A Phase I, Open-Label, Two-Part, Multicenter Perjeta Subcutaneous Dose-Finding Study in Combination With Herceptin in Healthy Male Volunteers and Female Patients With Early Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer; Early breast cancer
- Focus Pharmacokinetics
- Sponsors Roche
- 05 Jan 2018 Planned End Date changed from 15 Aug 2018 to 19 Jun 2018.
- 05 Jan 2018 Planned primary completion date changed from 15 Aug 2018 to 19 Jun 2018.
- 05 Jan 2018 Status changed from recruiting to active, no longer recruiting.